Abstract

ABCG2 is an efflux transporter commonly found to overexpress in multidrug resistant (MDR) cancer cells. It is also believed to be a survival factor for cancer stem cells to drive tumor growth. Tumor microenvironment represents an attractive new drug target because it allows complex interaction between a tumor and its surrounding normal cells, molecules, and blood vessels, which all participate in tumor progression. Hypoxia, glucose deprivation and acidosis are the hallmarks of tumor microenvironment. This study investigated the upregulation of ABCG2 by these adverse growth conditions within the tumor microenvironment. Reporter gene assay revealed that a region within the ABCG2 promoter close to the reported HIF-1α response element is responsible for ABCG2 upregulation. Increased ABCG2 efflux activity was observed under the same conditions, subsequently leading to reduced response to ABCG2 substrate anticancer drug. Importantly, glucose deprivation and hypoxia were also found to enhance the resistance level of ABCG2-overexpressing resistant cells with pre-existing genetic and epigenetic MDR mechanisms. Hypoxia was further demonstrated to cause a more malignant anchorage-independent growth phenotype in the resistant cells, which can be abolished by knocking down ABCG2. A better understanding of ABCG2 regulation by the tumor microenvironment may help design novel strategies to improve treatment outcome.

Highlights

  • Multidrug resistance (MDR) remains a major unresolved obstacle to successful cancer chemotherapy

  • The ABCG2 mRNA expression was evaluated in three human colon carcinoma cell lines (HCT-116, S1 and its resistant subline S1M1-80) after the pretreatment with glucose depletion, 2-DG, acidic pH and hypoxia

  • The increase in ABCG2 mRNA after 2-DG or hypoxia treatment was blocked by actinomycin D (5 μg/mL; data not shown), suggesting that these tumor microenvironment conditions regulate ABCG2 mRNA levels through an effect on ABCG2 transcription

Read more

Summary

Introduction

Multidrug resistance (MDR) remains a major unresolved obstacle to successful cancer chemotherapy. It is usually associated with an increased efflux of cytotoxic drugs by ATPbinding cassette (ABC) transporters including ABCG2. Identification of factors that can influence ABCG2 expression and activity might lead to the development of new strategies to modulate ABCG2mediated drug transport clinically. Resistant cancer cells often express high levels of the multidrug resistance (MDR) transporters as their biochemical mechanism of drug resistance. ABCG2 may contribute to the maintenance of stem or progenitor cells as a survival factor. Among the various conditions within the tumor microenvironment, hypoxia has been demonstrated to upregulate ABCG2 in a mouse progenitor cell model [3].

Objectives
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call